ACCEPTED MANUSCRIPT
2.
Wright, G. D., Something old, something new: revisiting natural products in antibiotic drug
discovery. Can. J. Microbiol. 2014, 60 (3), 147-54.
3.
Ventola, C. L., The antibiotic resistance crisis: part 1: causes and threats. P T 2015, 40 (4), 277-
83.
4.
Bush, K.; Courvalin, P.; Dantas, G.; Davies, J.; Eisenstein, B.; Huovinen, P.; Jacoby, G. A.;
Kishony, R.; Kreiswirth, B. N.; Kutter, E.; Lerner, S. A.; Levy, S.; Lewis, K.; Lomovskaya, O.; Miller, J.
H.; Mobashery, S.; Piddock, L. J.; Projan, S.; Thomas, C. M.; Tomasz, A.; Tulkens, P. M.; Walsh, T. R.;
Watson, J. D.; Witkowski, J.; Witte, W.; Wright, G.; Yeh, P.; Zgurskaya, H. I., Tackling antibiotic
resistance. Nat. Rev. Microbiol. 2011, 9 (12), 894-6.
5.
and Prevention: Atlanta, GA, USA, 2013; p 114.
6. de Kraker, M. E.; Stewardson, A. J.; Harbarth, S., Will 10 million people die a year due to
antimicrobial resistance by 2050? PLoS Med. 2016, 13 (11), e1002184.
7. Gorak, E. J.; Yamada, S. M.; Brown, J. D., Community-acquired methicillin-resistant
Frieden, T., Antibiotic Resistance Threats in the United States, 2013. Centers for Disease Control
Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin. Infect. Dis.
1999, 29 (4), 797-800.
8.
Stevens, A. M.; Hennessy, T.; Baggett, H. C.; Bruden, D.; Parks, D.; Klejka, J., Methicillin-
Resistant Staphylococcus aureus carriage and risk factors for skin infections, Southwestern Alaska, USA.
Emerg. Infect. Dis. 2010, 16 (5), 797-803.
9.
David, M. Z.; Rudolph, K. M.; Hennessy, T. W.; Boyle-Vavra, S.; Daum, R. S., Molecular
epidemiology of methicillin-resistant Staphylococcus aureus, rural southwestern Alaska. Emerg. Infect.
Dis. 2008, 14 (11), 1693-9.
10.
Johnson, J. K.; Khoie, T.; Shurland, S.; Kreisel, K.; Stine, O. C.; Roghmann, M. C., Skin and soft
tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 clone. Emerg. Infect.
Dis. 2007, 13 (8), 1195-200.
11.
Golding, G. R.; Levett, P. N.; McDonald, R. R.; Irvine, J.; Quinn, B.; Nsungu, M.; Woods, S.;
Khan, M.; Ofner-Agostini, M.; Mulvey, M. R.; Partnership, N. A. R., High rates of Staphylococcus
aureus USA400 infection, Northern Canada. Emerg. Infect. Dis. 2011, 17 (4), 722-5.
12.
Klevens, R. M.; Morrison, M. A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L. H.;
Lynfield, R.; Dumyati, G.; Townes, J. M.; Craig, A. S.; Zell, E. R.; Fosheim, G. E.; McDougal, L. K.;
Carey, R. B.; Fridkin, S. K.; Investigators, A. B. C. s. A. M., Invasive methicillin-resistant
Staphylococcus aureus infections in the United States. JAMA 2007, 298 (15), 1763-71.
13.
Drew, R. H., Emerging options for treatment of invasive, multidrug-resistant Staphylococcus
aureus infections. Pharmacotherapy 2007, 27 (2), 227-49.
14.
15.
Lowy, F. D., Staphylococcus aureus infections. N. Engl. J. Med. 1998, 339 (8), 520-32.
Rayner, C.; Munckhof, W. J., Antibiotics currently used in the treatment of infections caused by
Staphylococcus aureus. Intern. Med. J. 2005, 35 Suppl 2, S3-16.
16. Thati, V.; Shivannavar, C. T.; Gaddad, S. M., Vancomycin resistance among methicillin-resistant
Staphylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad. Indian J.
Med. Res. 2011, 134 (5), 704-8.
17.
Gilbert, D. N.; Kohlhepp, S. J.; Slama, K. A.; Grunkemeier, G.; Lewis, G.; Dworkin, R. J.;
Slaughter, S. E.; Leggett, J. E., Phenotypic resistance of Staphylococcus aureus, selected
Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to
ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob. Agents Chemother. 2001, 45 (3), 883-92.
18.
19.
Wright, G. D., Solving the Antibiotic Crisis. ACS Infect. Dis. 2015, 1 (2), 80-4.
Wright, G. D., Antibiotic adjuvants: rescuing antibiotics from resistance. Trends Microbiol. 2016,
24 (11), 862-871.
20.
Epand, R. M.; Walker, C.; Epand, R. F.; Magarvey, N. A., Molecular mechanisms of membrane
targeting antibiotics. Biochim. Biophys. Acta 2016, 1858 (5), 980-7.
16